We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation.
- Authors
Xu, Chong ‐ Rui; Zhong, Wen ‐ Zhao; Zhou, Qing; Zhang, Xu ‐ Chao; Yang, Jin ‐ Ji; Wu, Yi ‐ Long
- Abstract
We report the case of a 37-year-old male non-small cell lung cancer patient with an active epidermal growth factor receptor ( EGFR) mutation who received gefitinib as first-line treatment. After 13.7 months, the patient experienced disease progression and was treated with platinum-based doublet chemotherapy plus gefitinib for 5.4 months. A subsequent lung biopsy showed cMET overexpression; therefore, the patient received a cMET inhibitor with the gefitinib. The response in the different lesions of several organs was diverse. Stable disease was achieved in the lung lesion; however, the liver metastases enlarged. A liver biopsy found T790 M mutation in EGFR exon 20, thus, third generation EGFR-tyrosine kinase inhibitors were used and a partial response was achieved.
- Subjects
PROTEIN-tyrosine kinase inhibitors; GEFITINIB; PROTEIN kinase inhibitors; ANTINEOPLASTIC agents; BIOPSY; CANCER chemotherapy; DRUG resistance in cancer cells; EPIDERMAL growth factor; LIVER tumors; LUNG cancer; LUNG tumors; GENETIC mutation; DISEASE progression; THERAPEUTICS
- Publication
Thoracic Cancer, 2017, Vol 8, Issue 1, p51
- ISSN
1759-7706
- Publication type
Article
- DOI
10.1111/1759-7714.12382